CN104144950B - 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途 - Google Patents

含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途 Download PDF

Info

Publication number
CN104144950B
CN104144950B CN201280062050.1A CN201280062050A CN104144950B CN 104144950 B CN104144950 B CN 104144950B CN 201280062050 A CN201280062050 A CN 201280062050A CN 104144950 B CN104144950 B CN 104144950B
Authority
CN
China
Prior art keywords
glucosaminoglycan
heparin
chemical modification
molecular weight
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280062050.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104144950A (zh
Inventor
H-P·埃克勒
P-O·埃里克森
U·林达尔
E·霍尔默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Di Lefang LLC
Original Assignee
Di Lefang LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104144950(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Di Lefang LLC filed Critical Di Lefang LLC
Publication of CN104144950A publication Critical patent/CN104144950A/zh
Application granted granted Critical
Publication of CN104144950B publication Critical patent/CN104144950B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201280062050.1A 2011-12-19 2012-12-19 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途 Active CN104144950B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
US61/577,223 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Publications (2)

Publication Number Publication Date
CN104144950A CN104144950A (zh) 2014-11-12
CN104144950B true CN104144950B (zh) 2017-09-05

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280062050.1A Active CN104144950B (zh) 2011-12-19 2012-12-19 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途

Country Status (28)

Country Link
US (1) US9475888B2 (enExample)
EP (1) EP2794665B1 (enExample)
JP (2) JP6543467B2 (enExample)
KR (1) KR102135485B1 (enExample)
CN (1) CN104144950B (enExample)
AU (1) AU2012354229B2 (enExample)
BR (1) BR112014014454B1 (enExample)
CA (1) CA2856492C (enExample)
CL (1) CL2014001651A1 (enExample)
CO (1) CO7061069A2 (enExample)
CY (1) CY1119899T1 (enExample)
DK (1) DK2794665T3 (enExample)
ES (1) ES2656613T3 (enExample)
HR (1) HRP20180124T1 (enExample)
HU (1) HUE036523T2 (enExample)
IL (1) IL232905A (enExample)
LT (1) LT2794665T (enExample)
ME (1) ME02994B (enExample)
MX (1) MX351104B (enExample)
NO (1) NO2904345T3 (enExample)
PL (1) PL2794665T3 (enExample)
PT (1) PT2794665T (enExample)
RS (1) RS56874B1 (enExample)
RU (1) RU2617764C2 (enExample)
SI (1) SI2794665T1 (enExample)
SM (1) SMT201800143T1 (enExample)
WO (1) WO2013095279A1 (enExample)
ZA (1) ZA201403640B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
MY175743A (en) * 2012-03-26 2020-07-07 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
HK1203370A1 (en) * 2012-03-26 2015-10-30 迪乐方有限责任公司 Method for treatment of labor arrest
CA2868403A1 (en) * 2012-05-08 2013-11-14 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
JP2017522392A (ja) * 2014-04-30 2017-08-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ヘパラン硫酸
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
BR112022014456A2 (pt) 2020-02-17 2022-09-13 Dilafor Ab Tafoxiparina para o tratamento da pré-eclâmpsia
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
US20230355658A1 (en) 2022-05-03 2023-11-09 Dilafor Ab Medical use of tafoxiparin
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990502A (en) * 1987-04-16 1991-02-05 Sanofi, S.A. Low molecular weight heparins of regular structure, their preparation and their biological uses.
CN1186502A (zh) * 1995-03-31 1998-07-01 汉弥尔登市立医院研究发展股份有限公司 抑制血栓形成的组合物和方法
CN101842392A (zh) * 2007-11-02 2010-09-22 动量制药公司 非抗凝血剂的多糖组合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
GB2299998B (en) * 1995-03-31 1997-03-26 Hamilton Civic Hospitals Res Compositions for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
EP0867452A4 (en) 1996-10-15 2000-07-26 Toray Industries MATURATION AGENT FOR CERVICAL CHANNELS
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
AU1173599A (en) * 1997-11-20 1999-06-15 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
EP1059304B1 (en) 1998-02-26 2006-04-26 Seikagaku Corporation Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
KR20010030803A (ko) * 1998-07-31 2001-04-16 야마야 와따루 신규 글리코사미노글리칸 및 이를 함유하는 의약 조성물
JP2002523522A (ja) * 1998-08-26 2002-07-30 ザ コラボレイティブ グループ，リミテッド． 非誘導化水溶性ベータ−（１，３）−グルカンのレセプター
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
CA2422059C (en) * 2000-09-12 2012-05-15 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2003088980A1 (en) 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CA2616230A1 (en) 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
WO2007014049A2 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compositions and selectin inhibition
EP2016394A4 (en) * 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
WO2007140231A2 (en) * 2006-05-25 2007-12-06 Momenta Pharmaceutical, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8445436B2 (en) 2007-12-03 2013-05-21 Florida State University Research Foundation, Inc. Oxytocin and melatonin compositions and associated methods for inducing labor
EP2281008B1 (en) 2008-04-04 2017-01-04 University of Utah Research Foundation Alkylated and sulfated hyaluronan compounds, methods for their preparation and use thereof
WO2010111570A1 (en) * 2009-03-27 2010-09-30 E. I. Du Pont De Nemours And Company Polyglycerol aldehydes
ES2458818T3 (es) 2009-04-16 2014-05-07 Momenta Pharmaceuticals, Inc. Métodos para evaluar la actividad de una composición de polisacárido
US20120108538A1 (en) 2009-06-30 2012-05-03 James Beeson Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
CA2769258A1 (en) * 2009-07-31 2011-02-03 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
US9066991B2 (en) * 2009-12-22 2015-06-30 Lifebond Ltd. Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
HK1203370A1 (en) 2012-03-26 2015-10-30 迪乐方有限责任公司 Method for treatment of labor arrest
MY175743A (en) 2012-03-26 2020-07-07 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990502A (en) * 1987-04-16 1991-02-05 Sanofi, S.A. Low molecular weight heparins of regular structure, their preparation and their biological uses.
CN1186502A (zh) * 1995-03-31 1998-07-01 汉弥尔登市立医院研究发展股份有限公司 抑制血栓形成的组合物和方法
CN101842392A (zh) * 2007-11-02 2010-09-22 动量制药公司 非抗凝血剂的多糖组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
肝素降解和低分子量肝素的制备;张万忠等;《中国生化药物杂志》;20010131;第22卷(第1期);第48-51页 *

Also Published As

Publication number Publication date
MX2014007122A (es) 2015-03-05
RU2617764C2 (ru) 2017-04-26
ME02994B (me) 2018-10-20
SI2794665T1 (en) 2018-03-30
CA2856492C (en) 2017-01-10
CA2856492A1 (en) 2013-06-27
PL2794665T3 (pl) 2018-04-30
LT2794665T (lt) 2017-12-27
ZA201403640B (en) 2017-06-28
KR20140113652A (ko) 2014-09-24
JP2015500388A (ja) 2015-01-05
DK2794665T3 (da) 2018-01-29
MX351104B (es) 2017-10-02
RS56874B1 (sr) 2018-04-30
HK1202883A1 (en) 2015-10-09
EP2794665A1 (en) 2014-10-29
CN104144950A (zh) 2014-11-12
JP6543467B2 (ja) 2019-07-10
CO7061069A2 (es) 2014-09-19
HRP20180124T1 (hr) 2018-02-23
WO2013095279A1 (en) 2013-06-27
BR112014014454A2 (pt) 2017-06-13
US20150011505A1 (en) 2015-01-08
SMT201800143T1 (it) 2018-05-02
AU2012354229A1 (en) 2014-06-05
NO2904345T3 (enExample) 2018-07-21
KR102135485B1 (ko) 2020-07-17
IL232905A0 (en) 2014-07-31
BR112014014454B1 (pt) 2021-03-09
AU2012354229B2 (en) 2016-12-01
US9475888B2 (en) 2016-10-25
RU2014129816A (ru) 2016-02-20
ES2656613T3 (es) 2018-02-27
HUE036523T2 (hu) 2018-07-30
JP2018111825A (ja) 2018-07-19
EP2794665B1 (en) 2017-11-22
PT2794665T (pt) 2018-01-24
IL232905A (en) 2017-02-28
EP2794665A4 (en) 2015-08-26
CL2014001651A1 (es) 2014-10-10
CY1119899T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
CN104144950B (zh) 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
CN104053675B (zh) 低抗凝血肝素
US10023659B2 (en) Processes for the production of chemically-modified heparins
CA2868403A1 (en) Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
HK1202883B (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
CN118459618A (zh) 一种新型的半乳糖基化糖胺聚糖及其制备方法和用途
HK1220475B (en) New processes for the production of chemically-modified heparins
HK1200471B (en) Low anticoagulant heparins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant